Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Berger Financial Group Inc

Berger Financial Group Inc grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 352 shares of the biopharmaceutical company’s stock after acquiring an additional 18 shares during the period. Berger Financial Group Inc’s holdings in Regeneron Pharmaceuticals were worth $253,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. NewSquare Capital LLC grew its stake in shares of Regeneron Pharmaceuticals by 1,450.0% in the first quarter. NewSquare Capital LLC now owns 31 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 29 shares in the last quarter. Sunbelt Securities Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $25,000. Manchester Capital Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 740.0% in the first quarter. Manchester Capital Management LLC now owns 42 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 37 shares in the last quarter. BerganKDV Wealth Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 444.4% in the second quarter. BerganKDV Wealth Management LLC now owns 49 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 40 shares in the last quarter. Finally, Activest Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $40,000. Institutional investors and hedge funds own 84.15% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.2 %

Shares of REGN opened at $792.38 on Thursday. The company has a current ratio of 5.18, a quick ratio of 4.47 and a debt-to-equity ratio of 0.11. The firm’s 50-day moving average is $818.65 and its two-hundred day moving average is $781.70. Regeneron Pharmaceuticals, Inc. has a twelve month low of $668.00 and a twelve month high of $853.97. The firm has a market capitalization of $86.33 billion, a P/E ratio of 22.60, a PEG ratio of 3.00 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $11.59 earnings per share for the quarter, topping the consensus estimate of $9.58 by $2.01. Regeneron Pharmaceuticals had a net margin of 30.47% and a return on equity of 18.61%. The company had revenue of $3.36 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same period in the prior year, the business posted $9.98 earnings per share. The firm’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

REGN has been the subject of several recent analyst reports. StockNews.com initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, October 5th. They set a “buy” rating for the company. Barclays lifted their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $925.00 and gave the stock an “overweight” rating in a research report on Monday, August 21st. Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $915.00 to $914.00 and set an “overweight” rating for the company in a research report on Friday, November 3rd. Raymond James raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $950.00 price objective for the company in a research report on Friday, November 3rd. Finally, Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $720.00 to $992.00 in a research report on Monday, August 21st. One analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $903.64.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $827.90, for a total value of $82,790.00. Following the sale, the director now owns 18,547 shares of the company’s stock, valued at $15,355,061.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $827.90, for a total value of $82,790.00. Following the sale, the director now owns 18,547 shares of the company’s stock, valued at $15,355,061.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bonnie L. Bassler sold 853 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $829.00, for a total transaction of $707,137.00. Following the transaction, the director now directly owns 1,247 shares in the company, valued at approximately $1,033,763. The disclosure for this sale can be found here. Insiders have sold 34,356 shares of company stock valued at $28,811,415 over the last quarter. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.